logo
Yes, You Should Wear Compression Socks on Flights—a Former Nurse Shares the Important Reason Why

Yes, You Should Wear Compression Socks on Flights—a Former Nurse Shares the Important Reason Why

Travel + Leisure10 hours ago

While it's a completely normal occurrence to experience leg, ankle, and foot swelling on a flight, it can be pretty uncomfortable. Rather than endure the physical distress, you can invest in a pair of flight attendant-approved compression socks.
Karen Young, a nurse-turned-flight attendant with nearly 50 years of experience in the latter role, shared with Travel + Leisure why compression socks should always be a part of your airport outfits. Read on to learn more about the benefits of compression socks, and shop her top picks from Amazon's fashion store, where these important travel essentials start at $20.
Before becoming a flight attendant, Young was a nurse who would recommend compression socks for patients with circulatory and cardiac issues as they increase blood flow to the heart, which in turn, supports a healthy circulatory system.
Now, working as a flight attendant, she says compression socks are 'wonderful' for travelers who want to ease swelling and avoid getting enlarged veins (a.k.a varicose veins); both are common during a flight because the change in air pressure, combined with dehydration and sitting down for long periods of time, leads to blood pooling in your leg veins, according to the Mayo Clinic. Fluids then leave your blood and go into the soft tissue, causing your legs and other parts of your body to swell.
Compression socks use pressure on your legs to encourage blood flow, which can reduce swelling in the legs and feet, and in more severe cases, prevent blood clotting. When Young was a nurse, she and her colleagues regularly recommended Jobst compression socks, which range from $26 to $74, but Amazon has comparable picks for less than $20. Keep scrolling to shop the best compression socks ahead of your next flight.
These compression socks from CharmKing use controlled pressure to help stimulate blood flow so it doesn't pool into your lower extremities from inactivity on the plane. The stretchy material makes them easy to pull over your legs, and the knee-high length will help provide relief throughout your leg. Young added that it's common to see flight attendants wearing compression socks on flights, and the reviews for this style prove it. In their Amazon review, one flight attendant said these prevent their calves from aching after a long day in the air on their feet.
This three-pack of compression socks includes a mix of neutral colors you can pair with any of your airport outfits and are 'very comfortable,' according to a flight attendant. They also said that they reduced their aches and pains. Another one wrote that their legs were 'noticeably less swollen and felt less sore at the end of the day.'
These compression socks have earned more than 60,000 five-star ratings, including one from a flight attendant who said that since wearing them, their feet feel better and 'recover faster.' They also have a reinforced heel for extra comfort and to help prevent uncomfortable rubbing in your shoes.
Dr. Scholl's compression socks are American Podiatric Medical Association (APMA)-approved for promoting good foot health. They're made with mild compression to help encourage blood circulation and have the brand's comfortable Stay-Up Top cuff to prevent the socks from rolling down.
You can wear these Aoliks compression socks on the plane and your hikes; they're that versatile. The pressure provided on your legs helps with swelling and achy feet per the brand, which is especially helpful on long days of trekking up trails. One reviewer wears them on every flight, and said their legs no longer throb and they don't have restless leg syndrome.
If your feet are prone to sweating, you'll want to throw on these compression socks made from a breathable and comfortable material. One shopper, who's on their feet for up to 15 hours a day working across as many as four flights, said these socks make it so their toes 'don't feel like they're going to pop off like little sausages.' They continued, 'And I can see my ankles. These are miracle socks.'
Featuring a mix of nylon and spandex materials, these compression socks have a soft, stretchy feel that'll help keep your feet comfy and less swollen. The bottom comes with a non-slip design for extra stability, and the built-in heel cushion will add a layer of protection from blisters caused by shoes. One flight attendant called these their 'must-haves' for air travel, saying they noticed an immediate difference from the first wear, including their legs not being sore and feet not swollen.
Love a great deal? Sign up for our T+L Recommends newsletter and we'll send you our favorite travel products each week.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore

Yahoo

time22 minutes ago

  • Yahoo

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 7.5%. This drop was discouraging since the S&P 500 held steady. The elite companies can churn out earnings growth under any circumstance, however, and our mission at StockStory is to help you find them. Taking that into account, here are two healthcare stocks we think can generate sustainable market-beating returns and one we're steering clear of. Market Cap: $4.48 billion Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders. Why Is IRTC Not Exciting? Issuance of new shares over the last five years caused its earnings per share to fall by 5.6% annually while its revenue grew Cash-burning history makes us doubt the long-term viability of its business model 124× net-debt-to-EBITDA ratio shows it's overleveraged and increases the probability of shareholder dilution if things turn unexpectedly iRhythm's stock price of $138.38 implies a valuation ratio of 78.4x forward EV-to-EBITDA. If you're considering IRTC for your portfolio, see our FREE research report to learn more. Market Cap: $3.51 billion Pioneering treatments for a devastating childhood muscle-wasting disease that primarily affects boys, Sarepta Therapeutics (NASDAQ:SRPT) develops and commercializes RNA-targeted therapies and gene therapies for rare genetic disorders, primarily Duchenne muscular dystrophy. Why Do We Love SRPT? Market share has increased this cycle as its 51.3% annual revenue growth over the last two years was exceptional Earnings per share grew by 41% annually over the last five years, massively outpacing its peers Cash-burning tendencies have improved over the last five years, showing it could become financially independent one day At $35.74 per share, Sarepta Therapeutics trades at 3.5x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it's free. Market Cap: $14.82 billion With a network spanning nine states and serving primarily urban and suburban communities, Tenet Healthcare (NYSE:THC) operates a nationwide network of hospitals, ambulatory surgery centers, and outpatient facilities providing acute care and specialty healthcare services. Why Do We Like THC? Share repurchases have amplified shareholder returns as its annual earnings per share growth of 30.7% exceeded its revenue gains over the last five years Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures, and its returns are growing as it capitalizes on even better market opportunities Returns on capital are climbing as management makes more lucrative bets Tenet Healthcare is trading at $159.57 per share, or 13x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy
Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy

Yahoo

time22 minutes ago

  • Yahoo

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy

Sarepta Therapeutics has announced new outcomes from its open-label Phase Ib Study 9001-103, also referred to as the ENDEAVOR trial, of adeno-associated virus (AAV)-based gene transfer therapy Elevidys (delandistrogene moxeparvovec-rokl) to treat Duchenne muscular dystrophy (DMD). The multi-cohort ENDEAVOR study is aimed at evaluating the therapy's safety and protein expression in male subjects with DMD. Across seven cohorts, the trial enrolled 55 subjects and dosed participants who were aged between four and seven years old at the time of treatment, with varying degrees of mobility, and those younger than four years old. The primary endpoint of the trial is the change from baseline in Elevidys micro-dystrophin protein expression quantity at 12 weeks, as per western blot measurement, with secondary outcomes measuring dystrophin-positive fibres. In addition, the trial's exploratory endpoints evaluate the change in vector genome copies per nucleus, the North Star Ambulatory Assessment (NSAA), and timed functional tests. Inclusive of the first 12-week duration, subjects will undergo a follow-up period of a total of five years. In cohort 6, subjects aged two years old at the time of treatment showed a mean expression of 93.87% of normal dystrophin levels when treated with the therapy, with 79.9% dystrophin-positive fibres. These outcomes were observed in biopsies 12 weeks post-treatment. The safety seen in this cohort was found to be in line with the clinical and real-world applications of the therapy. Sarepta noted that the company has shared safety and expression from the trial's cohort 4, in which subjects were aged three at the time of treatment and showed a mean protein level of 99.64% in biopsies taken at the same post-treatment interval. More than 25 subjects below four years of age were treated in Sarepta's clinical trials. Sarepta Therapeutics research and development head and chief scientific officer Louise Rodino-Klapac said: 'The strength of the biomarker results that we are seeing in younger patients is extremely encouraging, and we have a meeting with the US Food and Drug Administration next month to discuss expanding the Elevidys label to include younger patients.' Last December, Sarepta completed enrolment and dosing for the Phase III EMERGENE trial of SRP-9003 (bidridistrogene xeboparvovec), targeting limb-girdle muscular dystrophy Type 2E/R4. "Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store